Change in use of proceeds from the global offering
Filed with HKEX · Stock code 2565 · · 7 pages · English
Earlier from PegBio
- Proposed change of auditor
- Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment
- Next Day Disclosure Return
- List of directors and their roles and functions
Later from PegBio
- 2026 Interim Report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- (1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting
- Notice of the 2026 first extraordinary general meeting
- Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026
Follow PegBio into a list and get an email when it puts out news.
Follow PegBio